Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Both inflammatory activation and dysregulation of the immune response in the bone marrow niche are key players in the pathogenesis of myelodysplastic syndromes (MDS). Manja…
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.
Analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy was associated with favorable survival outcomes vs…
A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.
The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of…
An abstract is unavailable.
Even if you’re in remission or you show no evidence of disease, you may still have fears that cancer may return. We spoke with our…